IR(1): Restaging CT 1 at 3 weeks demonstrates overall progression of tumor burden (SPD +124% from baseline) as evidenced interval increase in a right upper lobe lung mass (black arrow), left-sided pleural masses (asterisks), and left retrocrural lymphadenopathy (white arrow), and interval development of a large left-sided pleural effusion. Subsequent follow-up at 7 weeks (restaging CT 2) shows an interval decrease in size of all lesions with resolution of the left pleural effusion (SPD −27% from baseline). Additional follow-up at 13 weeks (restaging CT 3) demonstrates a further interval decrease in tumor burden, and the patient achieved a PR by revised response criteria (SPD −54% from baseline) with clear subsequent clinical benefit from continued treatment.